Antisense Therapeutics getting traction in the US, page-13

World first study* to assess up to 7,000 plasma proteins in Long COVID-19 patients  Collaboration with a global leader in the clinical research of neurological aspects of Long COVID-19  Study to look for blood disease markers to assess if amenable to treatment including with ATL1102  Retained blood samples from patients to be tested in the US by leading proteomics group First results from testing anticipated in mid-2022Antisense Therapeutics Limited [ASX: ANP | US OTC: ATHJY | FSE: AWY] (the Company) today announced the signing of an agreement and the start of a collaboration to study the neurological aspects of Long COVID-19 (Long Neuro COVID-19) with US based researchers led by Dr Igor Koralnik at the Northwestern Medicine Neuro-COVID clinic in Chicago, USA. Dr Koralnik is a global leader in the field, having treated over 1,000 patients with Long COVID-19 and having published on the subject matter in peer review journals1,2. The collaboration is not of a fixed term and will continue through the analysis and reporting of the research results.Under the collaboration, Dr Koralnik will provide existing blood samples, collected from previously studied Long COVID-19 patients including those with neurological symptoms where blood immune cell changes were observed1, to generate new data on up to 7,000 protein changes in these blood samples utilising a large-scale protein analysis known as proteomics.



Bingo ! The comprehensive study by Stanford University already embraces the fact that Long Covid brain data is similar to Alzheimer’s and Parkinson’s.(inflammation in the brain)
Anp has already shown in the MS trial it reduces brain lesions…

Itsa: has no doubt that this study is bigger than the DMD market.. $$$$ billions.